Literature DB >> 32289451

Quantitative MRI and laser ablation-inductively coupled plasma-mass spectrometry imaging of iron in the frontal cortex of healthy controls and Alzheimer's disease patients.

Marjolein Bulk1, Walid M Abdelmoula2, Hanneke Geut3, Wim Wiarda4, Itamar Ronen5, Jouke Dijkstra5, Louise van der Weerd6.   

Abstract

Accumulation of iron within the cortex of Alzheimer's disease (AD) patients has been reported by numerous MRI studies using iron-sensitive methods. Validation of iron-sensitive MRI is important for the interpretation of in vivo findings. In this study, the relation between the spatial iron distribution and T2∗-weighted MRI in the human brain was investigated using a direct comparison of spatial maps of iron as detected by T2∗-weighted MRI, iron histochemistry and laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS), in postmortem brain tissue of the medial frontal gyrus of three control subjects and six AD patients. In addition, iron levels measured by LA-ICP-MS and three quantitative MRI methods, namely R2∗ (=1/T2∗), image phase and quantitative susceptibility mapping (QSM), were compared between 19 AD and 11 controls. Histochemistry results we obtained with the modified Meguro staining were highly correlated with iron levels as detected by LA-ICP-MS (r2 ​= ​0.82, P ​< ​0.0001). Significant positive correlations were also found between LA-ICP-MS and the three quantitative MRI measurements: R2∗ (r2 ​= ​0.63), image phase (r2 ​= ​0.70) and QSM (r2 ​= ​0.74 (all p ​< ​0.0001)). R2∗ and QSM showed the strongest correlation with iron content; the correlation of phase with iron clearly showed increased variation, probably due to its high orientation dependence. Despite the obvious differences in iron distribution patterns within the cortex between AD patients and controls, no overall significant differences were found in iron as measured by LA-ICP-MS, nor in R2∗, phase or susceptibility. In conclusion, our results show that histochemistry as well as quantitative MRI methods such as R2∗ mapping and QSM provide reliable measures of iron distribution in the cortex. These results support the use of MRI studies focusing on iron distribution in both the healthy and the diseased brain.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Cortex; Iron; Mass spectrometry; Post mortem MRI; QSM

Mesh:

Substances:

Year:  2020        PMID: 32289451     DOI: 10.1016/j.neuroimage.2020.116808

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  5 in total

1.  Apolipoprotein E potently inhibits ferroptosis by blocking ferritinophagy.

Authors:  Ashley I Bush; Scott Ayton; Abdel Ali Belaidi; Shashank Masaldan; Adam Southon; Pawel Kalinowski; Karla Acevedo; Ambili T Appukuttan; Stuart Portbury; Peng Lei; Puja Agarwal; Sue E Leurgans; Julie Schneider; Marcus Conrad
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

Review 2.  Cerebral Iron Deposition in Neurodegeneration.

Authors:  Petr Dusek; Tim Hofer; Jan Alexander; Per M Roos; Jan O Aaseth
Journal:  Biomolecules       Date:  2022-05-17

3.  Off-resonance saturation as an MRI method to quantify mineral- iron in the post-mortem brain.

Authors:  Lucia Bossoni; Ingrid Hegeman-Kleinn; Sjoerd G van Duinen; Marjolein Bulk; Lena H P Vroegindeweij; Janneke G Langendonk; Lydiane Hirschler; Andrew Webb; Louise van der Weerd
Journal:  Magn Reson Med       Date:  2021-10-15       Impact factor: 3.737

Review 4.  Iron and Alzheimer's Disease: From Pathology to Imaging.

Authors:  Dean Tran; Phillip DiGiacomo; Donald E Born; Marios Georgiadis; Michael Zeineh
Journal:  Front Hum Neurosci       Date:  2022-07-13       Impact factor: 3.473

Review 5.  Role of micronutrients in Alzheimer's disease: Review of available evidence.

Authors:  Hong-Xin Fei; Chao-Fan Qian; Xiang-Mei Wu; Yu-Hua Wei; Jin-Yu Huang; Li-Hua Wei
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.